


In the Claims

1. (Currently Amended) A compound of formula (I):



wherein

R5 is selected from the group consisting of 3-pyridyl, 5-pyrimidinyl, -CONH-(C₁-C₄ alkyl), -NHCO-(C₁-C₄ alkyl), halogen, -SO₂NH₂, [[-NO₂,] -CF₃ or thien-2-ylcarbonyl and -CO₂R where R can be hydrogen or C₁-C₄ alkyl; and

Ar is selected from the group consisting of 5-imidazolyl, 2-pyrrolyl optionally substituted by a C₁-C₄ alkyl radical, 2-furyl or 2-thiazolyl, in the E or Z geometrical isomeric form or a mixture of the two geometrical isomeric forms.

2. (Original) The compound according to Claim 1, wherein R5 is a 3-pyridyl or -CONH-methyl or -NHCO-methyl.

3. (Original) The compound according to Claim 1 or 2, wherein Ar is a 5-imidazolyl or a 5-(4-methylimidazolyl) or a 2-pyrrolyl group.

4. (Original) The compound according to Claim 1, wherein it is selected from group of formulae consisting of:

1,3-dihydro-3-(imidazol-4-ylmethylene)-5-(pyrid-3-yl)-2H-indolin-2-one;
 1,3-dihydro-3-(pyrrol-2-ylmethylene)-5-(pyrid-3-yl)-2H-indolin-2-one;
 1,3-dihydro-3-(imidazol-4-ylmethylene)-5-(N-methylcarboxamido)-2H-indolin-2-one; and
 1,3-dihydro-3-(imidazol-4-ylmethylene)-5-(acetylamino)-2H-indolin-2-one.

Claims 5 and 6. (Cancelled)

7. (Original) A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to Claim 1 in a pharmaceutically acceptable medium.

Claims 8 to 12. (Cancelled)